Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park

Blood (2019) 134 (Supplement_1): 4426.

https://doi.org/10.1182/blood-2019-126839

Published: 2019

Journal Articles

Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children

Blood (2019) 134 (Supplement_1): 653.

https://doi.org/10.1182/blood-2019-125912

Published: 2019

Journal Articles

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Elisa Zuccarello, PhD, Elisa Calcagno, Adolfo Mazzeo, Nebiyu Ali Abshiru, PhD, Jeannie Camarillo, PhD, Neil L Kelleher, PhD, Changhong Qiao, Renu Nandakumar, PhD, Cremers Serge, PhD PharmD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD, PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2018) 132 (Supplement 1): 37.

https://doi.org/10.1182/blood-2018-99-110447

Published: 2018

Journal Articles

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Yuguang Wang, PhD, Hanying Bao, MD PhD, Nong Zhang, PhD, Feilan Wang, PhD, Yunsong He, MD, Tianzhi Wu, PhD

Blood (2018) 132 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2018-99-110414

Published: 2018

Journal Articles

Fetal Hemoglobin (HbF) Silencer BCL11A Acts through a Novel DNA-Motif in the Gamma-Globin Promoters, Simplifying the Model for Hemoglobin Switching

Nan Liu, PhD, Victoria V Hargreaves, PhD, Jiyoung Hong, PhD, Woojin Kim, PhD, Jesse Kurland, PhD, Qian Zhu, PhD, Falak Sher, PhD, Claudio Macias-Trevino, BS, Jill Rogers, PhD, Guo-Cheng Yuan, PhD, Daniel E. Bauer, MD PhD, Jian Xu, PhD, Martha L Bulyk, PhD, Stuart Orkin

Blood (2017) 130 (Supplement 1): 283.

https://doi.org/10.1182/blood.V130.Suppl_1.283.283

Published: 2017

Journal Articles

Cytopenia, Predisposition to Myelodysplastic Syndrome, Immunodeficiency, and Neurological Disease Caused By Gain-of-Function SAMD9L Mutations Is Frequently Ameliorated By Hematopoietic Revertant Mosaicism

Blood (2016) 128 (22): 4299.

https://doi.org/10.1182/blood.V128.22.4299.4299

Published: 2016

Journal Articles

Targeting ß -Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis

Angela A. Fachel, PhD, Ashlesha Shrikant Muley, MS, Cem Meydan, PhD, Xabier Agirre, PhD, Leandro Cerchietti, MD, Ari Melnick, MD, Kristy L. Richards, PhD MD

Blood (2016) 128 (22): 5382.

https://doi.org/10.1182/blood.V128.22.5382.5382

Published: 2016

Journal Articles

H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies

Blood (2016) 128 (22): 966.

https://doi.org/10.1182/blood.V128.22.966.966

Published: 2016

Journal Articles

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Mohammad Hojjat-Farsangi, PhD, Ali Moshfegh, PhD, Amir Hossein Daneshmanesh, MD PhD, Jan Vågberg, Byström Styrbjörn, Johan Schultz, Elisabeth Olsson, Charlotta Löfberg, Carina Norström, Martin Norin, Thomas Olin, PhD, Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD

Blood (2015) 126 (23): 2912.

https://doi.org/10.1182/blood.V126.23.2912.2912

Published: 2015

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD

Blood (2015) 126 (23): 3998.

https://doi.org/10.1182/blood.V126.23.3998.3998

Published: 2015

Journal Articles

Clinical Pharmacokinetics and Pharmacodynamics of Pwt-143, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110delta, Following Single Oral Administration to Healthy Volunteers

Ofir M Moreno, PhD, Vanessa Zann, PhD, Pui Leung, MD

Blood (2015) 126 (23): 4858.

https://doi.org/10.1182/blood.V126.23.4858.4858

Published: 2015

Journal Articles

Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) As a Potential Treatment for B-Cell Malignancies

Victoria Walker, PhD, Nicolas E S Guisot, PhD, Stuart Best, PhD, Fatima Talab, PhD, Catherine L Lucas, PhD, Julienne Refuerzo, Mathew Calder, Lauren Proctor, Melanie Muller, PhD, Kelvin Ho, PhD, Rose Chappell, Juliette Emmerich, PhD, Shona Harmon, PhD, Matilda Bingham, PhD, Mary-Ann Campbell, PhD, Richard Armer, PhD

Blood (2015) 126 (23): 4848.

https://doi.org/10.1182/blood.V126.23.4848.4848

Published: 2015

Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD

Blood (2014) 124 (21): 1783.

https://doi.org/10.1182/blood.V124.21.1783.1783

Published: 2014

Journal Articles

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Yiming Zhong, PhD, Shuai Dong, MS, Kelsey Thornton, Anjali Mishra, PhD, Pierluigi Porcu, MD, Michael Bradshaw, Angelina Bisconte, Timothy Owens, Erik Verner, Ken Brameld, Jens Oliver Funk, MD, Ronald Hill, Amy J. Johnson, PhD, Jason A Dubovsky, PhD

Blood (2014) 124 (21): 272.

https://doi.org/10.1182/blood.V124.21.272.272

Published: 2014

Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD

Blood (2014) 124 (21): 906.

https://doi.org/10.1182/blood.V124.21.906.906

Published: 2014

Journal Articles

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

James Tsai, Elizabeth A Burton, PhD, Gaston Habets, PhD, Brian West, PhD, Paul Lin, MD, Henry Hsu, MD, Chao Zhang, PhD, Gideon Bollag, PhD

Blood (2014) 124 (21): 3743.

https://doi.org/10.1182/blood.V124.21.3743.3743

Published: 2014

Journal Articles

Modeling human tumor angiogenesis in a three-dimensional culture system

Giorgio Seano, Giulia Chiaverina, Paolo Armando Gagliardi, Laura di Blasio, Roberto Sessa, Federico Bussolino, Luca Primo

Blood (2013) 121 (21): e129–e137.

https://doi.org/10.1182/blood-2012-08-452292

Published: 2013

Includes: Multimedia, Supplemental data

Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 141.

https://doi.org/10.1182/blood.V120.21.141.141

Published: 2012

Journal Articles

PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.

Greg Coffey, PhD, Francis DeGuzman, PhD, Gail Lee, BS, Lynn Kamen, PhD, Dale Baker, PhD, Stanley J Hollenbach, BS, JD, Anjali Pandey, PhD, Uma Sinha, PhD

Blood (2012) 120 (21): 2764.

https://doi.org/10.1182/blood.V120.21.2764.2764

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Fetal Hemoglobin (HbF) Silencer BCL11A Acts through a Novel DNA-Motif in the Gamma-Globin Promoters, Simplifying the Model for Hemoglobin Switching

Cytopenia, Predisposition to Myelodysplastic Syndrome, Immunodeficiency, and Neurological Disease Caused By Gain-of-Function SAMD9L Mutations Is Frequently Ameliorated By Hematopoietic Revertant Mosaicism

Targeting ß -Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis

H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Clinical Pharmacokinetics and Pharmacodynamics of Pwt-143, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110delta, Following Single Oral Administration to Healthy Volunteers

Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) As a Potential Treatment for B-Cell Malignancies

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

Modeling human tumor angiogenesis in a three-dimensional culture system

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only